P156: Beyond height and growth: Impact of achondroplasia therapy on a cohort of Brazilian patients

Achondroplasia is the most common form of skeletal dysplasia. Individuals with achondroplasia may suffer from a range of serious and debilitating complications over the course of their lifetime: sleep disordered breathing, upper airway obstruction and ear, orthopedic problems, foramen magnum stenosis, among others. Recently, several drugs that modulate abnormally activated FGFR3 signaling have recently emerged, being vosoritide, a recombinant C-type natriuretic peptide (CNP) analog, the first specific drug approved for children with achondroplasia.